comprehensive -WSS

comprehensive

author：comprehensive 2025-09-06 04:42:18 - browse：98

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： CRISPR base editing slashes cholesterol levels in monkeys

WSS

New oral drug delivery patch is modeled after octopus tentacles

Advances in CAR

New oral drug delivery patch is modeled after octopus tentacles

New oral drug delivery patch is modeled after octopus tentacles

European officials brace for rough respiratory virus season

New oral drug delivery patch is modeled after octopus tentacles

leisure time

comprehensive

focus

Affirmative action in medical school literally saved lives

European officials brace for rough respiratory virus season

Wildfire smoke exposes gaps in outdoor worker protections

Trump surgeon general acknowledges mistakes during Covid

BioMarin wins approval for gene therapy to treat hemophilia A

RSV injection headlines need to be accurate for good uptake

At least 13 dead in Texas as scorching temps continue

What drug price negotiations mean for Medicare Part D

Dobbs anniversary: the lost opportunity of abortion as health care

The stability of $0 premiums in Medicare Advantage

hotspot

Setback for rare diseases as Taysha Gene Therapies pulls back

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

How to protect patients from sexual assault

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

RSV injection headlines need to be accurate for good uptake

New oral drug delivery patch is modeled after octopus tentacles

hotspot

focus

Wikipedia

explore